期刊文献+

氯桂丁胺对小鼠CYP450含量的影响及与大鼠血浆蛋白结合率 被引量:2

Effect of 3,4 - dichlorophenyl - propenoyl - sec. - butylamine on the Content of Cyp450 in Mice and Plasma Protein Binding Rate in Rats
下载PDF
导出
摘要 目的:研究氯桂丁胺对小鼠细胞色素P450(CYP450)含量的影响及与大鼠血浆蛋白结合率。方法:用分光 光度法测定CYP450含量,用平衡透析法测定蛋白结合率。结果:氯桂丁胺对小鼠肝脏CYP450酶总含量没有影响,氯桂 丁胺在血浆中的浓度为4-8μg/ml时,与大鼠血浆蛋白结合率为71.79%-73.56%,不同剂量组间药物与血浆蛋白的结 合率差异无显著性(P>0.05)。结论:氯桂丁胺对肝药酶无诱导或抑制作用,属中等蛋白结合率的药物。 Objective:To investigate the influence of DCPB (3,4 - dichlorophenyl - propenoyl - sec. - butylamine) on the content of cyp450 in mice and the plasm protein binding rate. Methods : the binding rate of DCPB to plasma protein was determined by equilibrium dialysis method, and the content of CYP450 was assayed by differential spectrum method. Results :The resuits showed that DCPB has no effect on the total content of CYP450 in mice, and the binding rate of DCPB to plasma protein was found to be 71.79% - 73.56% when the concentration of DCPB in plasma was 4 - 8μg/ml. There is no significant difference in the binding rate between different dose groups ( P 〉 0. 05 ). Conclusion : CYP450 was not induced or inhibited by DCPD whose protein binding rate is medium.
出处 《包头医学院学报》 CAS 2005年第4期339-341,共3页 Journal of Baotou Medical College
关键词 CYP450含量 血浆蛋白结合率 Content of CYP450 Plasma protein binding rate Rat
  • 相关文献

参考文献11

二级参考文献15

  • 1王迪 陶成.3,4-二氯苯丙烯酰另丁胺对小鼠脑缺血的保护作用[J].中国药理学会通讯,1996,13(3):27-27.
  • 2夏奕明 朱莲珍.血和组织中谷胱甘肽过程氧化物酶活力的测定方法[J].卫生研究,1987,16(4):29-29.
  • 3陈修 徐叔云 等.脑缺血模型制备.药理实验方法学,第2版[M].北京:人民卫生出版社,1991.502.
  • 4陈志顺.过氧化脂质TBA显色三种方法比较[J].临床检验杂志,1984,10(2):8-8.
  • 5王迪,中国药理学通讯,1996年,13卷,3期,27页
  • 6陈修,药理实验方法学(第2版),1991年,502页
  • 7Chu G X,中国药理学与毒理学杂志,1989年,3卷,1期,18页
  • 8夏奕明,卫生研究,1987年,16卷,4期,29页
  • 9陈志顺,临床检验杂志,1984年,10卷,2期,8页
  • 10许劲秋,李金恒,宫剑滨,李俭春.反相高效液相色谱法测定奎尼丁血药浓度[J].中国药理学通报,1998,14(3):278-279. 被引量:3

共引文献38

同被引文献16

  • 1李强,步秀云,章国良,楼雅卿.HPLC法测定大鼠血浆中氯桂丁胺浓度[J].药物分析杂志,2004,24(3):279-281. 被引量:1
  • 2王长虹,邹小广,孙殿甲,王峥涛.盐酸去氢骆驼蓬碱血浆蛋白结合率的测定[J].中国医院药学杂志,2005,25(2):99-101. 被引量:8
  • 3Mitchell K M, Dotson A L, Cool K M, et al. Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis [ J ]. Multi Scler, 2007, 13 ( 9 ) :1118-1126.
  • 4Angelucci E, Barosi G, Camaschella C, et al. Itahan Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders [ J ].Haematologica, 2008, 93 (5) : 741-752.
  • 5Liu P, Yao Y N, Wu S D, et al. The efficacy of deferiprone on tissues aluminum removal and copper, zinc, manganese level in rabbits[J]. J Inorg Biochem, 2005, 99(8) : 1733-1737.
  • 6Limenla L M, Jirasomprasert T, Tankanitlert J, et al. UGT1A6 genotype-related phannacokinetics of deferiprone (L1) in healthy volunteers[J].Bri J Clin Pharmacol, 2008, 65(5): 908-916.
  • 7Blanusa M, Vamai V M, Piasek M, et al. Chelators as antidotes of metal toxicity: therapeutic and experimental aspects [J]. Curr Med Chem, 2005, 12:2771-2794.
  • 8Li Q, Zhang GL, Bu XY, et al. Pharmacokinetics of 3,4 - dichlo- rophenyl - propenoyl - sec. - butylamine (7903) in rats [ J ]. Asi- an J Drug Metab Pharmacokinet, 2004 ; 4:205 - 208.
  • 9Wang SM, Dou GF, Li Q, et al. Pharmacokinetics and metabolism of 3,4 - dichlorophenyl - propenoyl - sec. - butylamine in rats by high performance liquid chromatography - ion trap mass spectrome- try [J]. J Chromatogr B, 2007; 850:92- 100.
  • 10Hickman D, Wang JP, Wang Y, et al. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measure- ment of human cytochrome P450 monooxygenase activities [J]. Drug Metab Dispos, 1998 ; 26:207 - 215.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部